Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAZNI: A Phase I/II Combination Trial of Tazemetostat With Nivolumab and Ipilimumab for Children With INI1-Negative or SMARCA4-Deficient Tumors

NCT05407441 is registered in ClinicalTrials.gov with Susan Chi, MD as lead sponsor.

NCT NCT05407441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05407441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAZNI: A Phase I/II Combination Trial of Tazemetostat With Nivolumab and Ipilimumab for Children With INI1-Negative or SMARCA4-Deficient Tumors
Lead sponsor
Susan Chi, MD
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 10, 2023
Completion date
February 1, 2029
Enrollment
49 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid rhabdoid tumor, chordoma, epithelioid sarcoma, ini1 (smarcb1)-deficient primary cns malignant tumors, malignant rhabdoid tumor (mrt), rhabdoid tumor of the kidney (rtk), smarca4-deficient primary cns malignant tumors